How COVID-19 has and will change the pharma sector

7 September 2020

Richard Bergström, long-standing board member of European Health Forum Gastein and former director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), provides an Expert View on the impact of COVID-19.

Just six months into the deadliest global pandemic for a century, the way we live has changed dramatically, most likely forever. For all of us, our children, yours, and mine, above all there will a pre- and post- COVID-19 world.

And healthcare systems have undergone and are still experiencing convulsive change. Let me reflect here on how the pharmaceutical industry has and will have changed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK